{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:30:53Z","timestamp":1790674253092,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1016\/j.ejca.2006.03.023","type":"journal-article","created":{"date-parts":[[2006,8,9]],"date-time":"2006-08-09T12:44:41Z","timestamp":1155127481000},"page":"2335-2342","source":"Crossref","is-referenced-by-count":82,"title":["Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours"],"prefix":"10.1016","volume":"42","author":[{"given":"S.","family":"Baruchel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Diezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Hargrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Stempak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gammon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Moghrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Coppes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.V.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bouffet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2006.03.023_bib1","first-page":"5846","article-title":"Antitumor activity and pharmacokinetics in mice of 8-carbomoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one, a novel drug with potential as an alternative dacarbazine","volume":"47","author":"Stevens","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2006.03.023_bib2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/bjc.1992.57","article-title":"Phase I trial of Temozolomide","volume":"65","author":"Newlands","year":"1992","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2006.03.023_bib3","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1158\/1078-0432.CCR-03-0807","article-title":"Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients","volume":"10","author":"Ostermann","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2006.03.023_bib4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1023\/A:1022592913323","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates","volume":"61","author":"Patel","year":"2003","journal-title":"J Neuro-oncol"},{"key":"10.1016\/j.ejca.2006.03.023_bib5","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0093-7754(01)90069-7","article-title":"Temozolomide for treating brain metastases","volume":"28","author":"Abrey","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2006.03.023_bib6","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0093-7754(01)90066-1","article-title":"Chemotherapy for the treatment of oligodendroglial tumors","volume":"28","author":"Chinot","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2006.03.023_bib7","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0093-7754(01)90065-X","article-title":"Temozolomide for recurrent high-grade glioma","volume":"28","author":"Macdonald","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2006.03.023_bib8","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0093-7754(01)90068-5","article-title":"Temozolomide in combination with other cytotoxic agents","volume":"28","author":"Prados","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2006.03.023_bib9","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(01)00489-2","article-title":"Current and future developments in the use of temozolomide for the treatment of brain tumors","volume":"2","author":"Stupp","year":"2001","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2006.03.023_bib10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0305-7372(97)90019-0","article-title":"Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials","volume":"23","author":"Newlands","year":"1997","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2006.03.023_bib11","first-page":"2585","article-title":"Temozolomide and treatment of malignant glioma","volume":"6","author":"Friedman","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2006.03.023_bib12","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1200\/JCO.1999.17.9.2762","article-title":"Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse","volume":"17","author":"Yung","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.03.023_bib13","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1054\/bjoc.2000.1316","article-title":"A phase II study of temozolomide vs. procarbazine in patients with glioblastomas multiforme at first relapse","volume":"83","author":"Yung","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2006.03.023_bib14","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1200\/JCO.2003.01.009","article-title":"Phase II trial of temozolomide in patients with progressive low-grade glioma","volume":"21","author":"Quinn","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.03.023_bib15","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0093-7754(01)90067-3","article-title":"New approaches for temozolomide therapy: use in newly diagnosed glioma","volume":"28","author":"Stupp","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2006.03.023_bib16","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1200\/JCO.20.5.1375","article-title":"Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide","volume":"20","author":"Stupp","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.03.023_bib17","first-page":"998","article-title":"Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models","volume":"6","author":"Middlemas","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2006.03.023_bib18","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1200\/JCO.2002.06.110","article-title":"Clinical relevance of MGMT in the treatment of cancer","volume":"20","author":"Gerson","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.03.023_bib19","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1158\/1078-0432.CCR-03-0384","article-title":"Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide","volume":"10","author":"Hegi","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2006.03.023_bib20","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/sj.bjc.6600827","article-title":"Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules","volume":"88","author":"Tolcher","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2006.03.023_bib21","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/bjc.1998.555","article-title":"Phase I study of temozolomide in paediatric patients with advanced cancer","volume":"78","author":"Estlin","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2006.03.023_bib22","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1200\/JCO.2002.08.141","article-title":"Temozolomide in malignant gliomas of childhood: a United Kingdom Children\u2019s Cancer Study Group and French Society for Pediatric Oncology Intergroup study","volume":"20","author":"Lashford","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.03.023_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/bies.950130106","article-title":"Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents","volume":"13","author":"Kerbel","year":"1991","journal-title":"Bioessays"},{"key":"10.1016\/j.ejca.2006.03.023_bib24","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1172\/JCI8829","article-title":"Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity","volume":"105","author":"Klement","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2006.03.023_bib25","first-page":"1878","article-title":"Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer","volume":"60","author":"Browder","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2006.03.023_bib26","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI9872","article-title":"Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice","volume":"105","author":"Hanahan","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ejca.2006.03.023_bib27","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1200\/JCO.2005.07.093","article-title":"A multitargeted, metronomic, and maximum-tolerated dose \u2018chemo-switch\u2019 regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer","volume":"23","author":"Pietras","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.03.023_bib28","first-page":"4363","article-title":"Phase I trial of temozolomide using an extended continuous oral schedule","volume":"58","author":"Brock","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2006.03.023_bib29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1215\/15228517-4-1-39","article-title":"A phase II study of extended low-dose temozolomide in recurrent malignant gliomas","volume":"4","author":"Khan","year":"2002","journal-title":"Neuro-oncol"},{"key":"10.1016\/j.ejca.2006.03.023_bib30","first-page":"117","article-title":"Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors","volume":"49","author":"Sterba","year":"2002","journal-title":"Neoplasma"},{"key":"10.1016\/j.ejca.2006.03.023_bib31","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/00043426-200305000-00005","article-title":"Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas","volume":"25","author":"Kuo","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.ejca.2006.03.023_bib32","unstructured":"Available from: http:\/\/ctep.cancer.gov\/reporting\/CTC-3test.html."},{"key":"10.1016\/j.ejca.2006.03.023_bib33","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1200\/JCO.2004.11.957","article-title":"Temozolomide for melanoma: new toxicities and new opportunities","volume":"22","author":"Gajewski","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.03.023_bib34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/neuonc\/4.4.261","article-title":"A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy","volume":"4","author":"Gilbert","year":"2002","journal-title":"Neuro-oncol"},{"key":"10.1016\/j.ejca.2006.03.023_bib35","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1200\/JCO.2003.12.097","article-title":"Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment or recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study","volume":"21","author":"Jaeckle","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.03.023_bib36","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/mpo.10221","article-title":"Response to low dose temozolomide in radiation induced gliomatosis cerebri","volume":"41","author":"Hargrave","year":"2003","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.ejca.2006.03.023_bib37","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2006.03.023_bib38","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1158\/0008-5472.CAN-04-0580","article-title":"A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens","volume":"64","author":"Emmenegger","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2006.03.023_bib39","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/00001813-200308000-00003","article-title":"Inhibition of angiogenesis by non-toxic doses of temozolomide","volume":"14","author":"Kurzen","year":"2003","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejca.2006.03.023_bib40","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00280-003-0678-9","article-title":"Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study","volume":"52","author":"Spieth","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2006.03.023_bib41","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/cncr.11775","article-title":"Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors","volume":"98","author":"Vogt","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2006.03.023_bib42","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/cncr.11713","article-title":"Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma","volume":"98","author":"Glode","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2006.03.023_bib43","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1006\/jtbi.2003.3162","article-title":"Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis","volume":"220","author":"Hahnfeldt","year":"2003","journal-title":"J Theor Biol"},{"key":"10.1016\/j.ejca.2006.03.023_bib44","first-page":"427","article-title":"Antiangiogenic scheduling of lower dose cancer chemotherapy","volume":"7","author":"Gately","year":"2001","journal-title":"Cancer J"},{"key":"10.1016\/j.ejca.2006.03.023_bib45","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/cncr.21564","article-title":"Salvage temozolomide for prior temozolomide responders","volume":"104","author":"Franceschi","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2006.03.023_bib46","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00280-003-0677-x","article-title":"Pharmacokinetics of temozolomide given three times a day in pediatric and adult patients","volume":"52","author":"Riccardi","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2006.03.023_bib47","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00280-003-0670-4","article-title":"Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors","volume":"52","author":"Panetta","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2006.03.023_bib48","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1200\/JCO.2004.07.060","article-title":"Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications","volume":"22","author":"Su","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2006.03.023_bib49","first-page":"4342","article-title":"Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells","volume":"63","author":"Bertolini","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2006.03.023_bib50","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1535-6108(04)00369-1","article-title":"Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: implications for cellular surrogate marker analysis of antiangiogenesis","volume":"7","author":"Shaked","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2006.03.023_bib51","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1038\/sj.bjc.6602474","article-title":"Can a rational design for metronomic chemotherapy dosing be devised?","volume":"92","author":"Maraveyas","year":"2005","journal-title":"Br J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804906005077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804906005077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,20]],"date-time":"2019-04-20T15:57:10Z","timestamp":1555775830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804906005077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":51,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["S0959804906005077"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2006.03.023","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}